Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.
about
Synthetic biology and microbioreactor platforms for programmable production of biologics at the point-of-careA dual-mode surface display system for the maturation and production of monoclonal antibodies in glyco-engineered Pichia pastorisEngagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activationProtein production from the structural genomics perspective: achievements and future needs.Generation of diploid Pichia pastoris strains by mating and their application for recombinant protein production.High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells.Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.Multi-parametric analysis reveals enhanced G2-phase arrest of an optimized anti-HER2 antibody to inhibit breast cancer.A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.Biochemical and biophysical characterization of humanized IgG1 produced in Pichia pastoris.Expression of recombinant antibodies.Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.Engineering yeast for producing human glycoproteins: where are we now?Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.Efficient production of single-chain fragment variable-based N-terminal trimerbodies in Pichia pastoris.HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.Antibody production using a ciliate generates unusual antibody glycoforms displaying enhanced cell-killing activity.Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer.Marketing approval of mogamulizumab: a triumph for glyco-engineering.Inactivation of a GAL4-like transcription factor improves cell fitness and product yield in glycoengineered Pichia pastoris strains.Online enzymatic sequencing of glycans from Trastuzumab by phospholipid-assisted capillary electrophoresis.A streamlined cloning workflow minimising the time-to-strain pipeline for Pichia pastoris.Production of Full-Length Antibody by Pichia pastoris.Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation.Enhanced truncated-t-PA (CT-b) expression in high-cell-density fed-batch cultures of Pichia pastoris through optimization of a mixed feeding strategy by response surface methodology.9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.Improvement of N-glycan site occupancy of therapeutic glycoproteins produced in Pichia pastoris.Adding Functions to Biomaterial Surfaces through Protein Incorporation.
P2860
Q27335294-475B632B-267E-4C10-9148-4E7E18E7BE35Q28534600-78AB3615-909A-4FD6-8C88-AB6572944812Q33739796-BF642239-8DBB-40C2-902D-019935CA945BQ34174863-27A89E33-6322-4B47-8DE0-AB9DD85907BCQ34322730-4205B7E0-28D5-4472-94BB-619451BF4B65Q34784806-CACDC0EA-D5E6-4508-A7F6-730B869F9ADDQ35705039-981C2611-1604-4268-B365-88459F0B2EF8Q35828597-5C44DBE4-BB6D-43C5-8938-F8B38A2C7170Q35992488-AE704510-2C64-4A7D-A055-54959AC761E4Q36385800-CA31313C-1AAD-454E-99D4-4114B71E6539Q36924491-6D7FAFED-72B3-4A85-9D88-AA600C04B7E3Q37138274-C455070A-50E4-4AB2-9DF3-2A25767E9F4EQ37952121-AF2BE6B4-6EA6-4FC8-BE04-C911D9F05A26Q38126016-3502F189-F44D-4D1F-A4EA-1193AD37F0A6Q38896842-44AC4814-B7CE-4FAD-A7D4-55A0DEBCDE2CQ39055068-A9D4DD47-1576-428D-AD1C-9380DA90CFA4Q39239280-D853A87A-25BC-400B-9E08-5D9550A2B58CQ41896587-A301C748-5144-4F91-80C2-C048946DFC90Q42104011-101AB124-F5C0-4962-8F97-0306045DB042Q42129626-2FFFF72D-9321-4E55-ADBE-5CD4E30C5B4CQ42320213-592B9D4A-BE7A-4F28-B811-F30D5CF73A09Q42333453-D9D8A187-95F9-43DE-A97B-473BA223C752Q43074457-DA66DDFA-E6C8-4570-8ACA-D27039C69505Q44970905-471E81AA-78DA-411E-82B0-DBA7F161D67BQ47137573-B55C3B98-2D8B-4AD4-BBF8-D5FBF17DB111Q47786955-9B3ED4E5-B944-498D-8E52-E44A7610BEF2Q50133462-E44B82A0-9A2D-4B72-83E0-E1A5EA952452Q50736521-09495F27-BA0F-4CAC-BCE5-7F68489D60FEQ51238255-D9C840E9-68C4-4689-A503-66A35584777DQ51759223-4AD4C954-F5D8-4B9F-A503-8DEB261F0B84Q53100671-353670F6-B032-462C-9E2B-13B28A5DD521
P2860
Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Glycoengineered Pichia produce ...... stuzumab in preclinical study.
@en
Glycoengineered Pichia produce ...... stuzumab in preclinical study.
@nl
type
label
Glycoengineered Pichia produce ...... stuzumab in preclinical study.
@en
Glycoengineered Pichia produce ...... stuzumab in preclinical study.
@nl
prefLabel
Glycoengineered Pichia produce ...... stuzumab in preclinical study.
@en
Glycoengineered Pichia produce ...... stuzumab in preclinical study.
@nl
P2093
P2860
P356
P1476
Glycoengineered Pichia produce ...... astuzumab in preclinical study
@en
P2093
Byung-Kwon Choi
Calin Dan Dumitru
Dongxing Zha
Hans E Huber
Irina Burnina
Liming Liu
Muralidhar R Mallem
P2860
P304
P356
10.4161/MABS.3.3.15532
P577
2011-05-01T00:00:00Z